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In recent years it has become clear that cancer cells
within a single tumor can display striking morphological,
genetic and behavioral variability. Burgeoning genetic,
epigenetic and phenomenological data support the
existence of intra-tumor genetic heterogeneity in breast
cancers; however, its basis is yet to be fully defined. Two
of the most widely evoked concepts to explain the
origin of heterogeneity within tumors are the cancer
stem cell hypothesis and the clonal evolution model.
Although the cancer stem cell model appeared to
provide an explanation for the variability among the
neoplastic cells within a given cancer, advances in
massively parallel sequencing have provided several
lines of evidence to suggest that intra-tumor genetic
heterogeneity likely plays a fundamental role in the
phenotypic heterogeneity observed in cancers. Many
challenges remain, however, in the interpretation of
the next generation sequencing results obtained so
far. Here we review the models that explain tumor
heterogeneity, the causes of intra-tumor genetic
diversity and their impact on our understanding and
management of breast cancer, methods to study
intra-tumor heterogeneity and the assessment of
intra-tumor genetic heterogeneity in the clinic.The theories describing the establishment and mainten-Introduction
Intra-tumor heterogeneity denotes the coexistence of sub-
populations of cancer cells that differ in their genetic,
phenotypic or behavioral characteristics within a given
primary tumor, and between a given primary tumor and
its metastasis. This diversity can be attributed to genetic
and epigenetic factors, and to non-hereditary mechanisms
such as adaptive responses or fluctuation in signaling
pathways [1,2]. Cancer cells within a given tumor may dif-
fer not only phenotypically or in relation to genetic aber-
rations that do not confer an overt phenotype, but also in
terms of their driver genetic aberrations. For instance,* Correspondence: weigeltb@mskcc.org; reisfilj@mskcc.org
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2014HER2 status may vary between primary tumors and their
respective metastasis or circulating tumor cells (CTCs)
[3,4], and examples of primary invasive breast cancers
containing neoplastic cells with and without HER2 ampli-
fication are on record [5]. Thus, intra-tumor heterogeneity
poses a tremendous challenge for the characterization of
biomarkers and treatment selection.
Massively parallel sequencing (MPS) studies of breast
cancers and other tumor types have shown that spatial
and temporal heterogeneity are common phenomena
[6-11]. Thus, biopsies of a small tumor region may not
provide a representative characterization of the genetic,
epigenetic and/or phenotypic alterations found in the
tumor as a whole [6,12]. It is now apparent that further
complexity is added to the challenges posed by intra-
tumor genetic heterogeneity when dimensions of space
and time are incorporated to reflect the dynamic nature of
tumors [13]. New insights into the underlying features,
mechanisms and consequences of tumor heterogeneity
and new approaches to characterizing intra-tumor genetic
heterogeneity are crucial for the improvement of existing
therapies and for the realization of the potential of preci-
sion medicine.Tumor heterogeneity
ance of tumor heterogeneity are the cancer stem cell
(CSC) hypothesis [14] and the clonal evolution/selection
model [15], two concepts that were initially thought to be
mutually exclusive, but are now perceived as potentially
complementary [2,16]. Both concepts consider that tumors
originate from single cells that have acquired multiple mo-
lecular alterations, have developed indefinite proliferative
potential, and assume that (micro)environmental cues
have an impact on the composition of a cancer. These the-
ories, however, have fundamental differences (Table 1);
while the CSC hypothesis attributes heterogeneity to
aberrant differentiation programs and presupposes the
existence of a hierarchical organization of cancer cells,
the clonal evolution model explains intra-tumor diver-
sity as speciation by natural selection and does not rely
on a hierarchical model. Importantly, the CSC hypothesistral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
is time, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Tenets of the cancer stem cell and clonal evolution models
Cancer stem cell model Clonal evolution model
Tumorigenic cells CSCs Any cell
Tumor cell organization Hierarchical Stochastic
Capacity of self-renewal with
asymmetric divisions
CSCs can self-renew indefinitely whereas terminally
differentiated cells have limited proliferative potential
Not applicable
Progression Driven by CSCs, which account for a small
subpopulation of the tumor bulk
Driven by the fittest clone under a constellation
of selective pressures
Source of heterogeneity Aberrant differentiation program and mutations Epigenetic and genetic aberrations followed by selection
Type of heterogeneity Initially perceived as largely phenotypic; however,
more recent studies suggested that CSCs may be
genetically heterogeneous within a tumor
Genetic and phenotypic heterogeneity
Source of resistance to therapy CSCs Selection of resistant subclones harboring specific
genetic or epigenetic aberrations
CSC, cancer stem cell.
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progression and are inherently therapy-resistant. For the
clonal evolution model, progression and resistance to
therapy would follow Darwinian evolutionary rules, where
the emergence of clones that would be able to progress or
be resistant to a given therapy would depend on the cell
population size, mutation rate (that is, genetic instability),
proliferation rate and selective pressures imposed by the
(micro)environment and/or external selective pressures
(for example, therapies) [17].
The cancer stem cell hypothesis
The CSC concept proposes that, within a given tumor, a
phenotypic hierarchy exists, with a minor subset of the
so-called CSCs at the apex and highly proliferating,
lineage-committed progenitors and terminally differenti-
ated cells at the base [18]. One of the tenets of this
model is that tumor growth, disease progression and the
generation of heterogeneity in cancers are driven by a
small population of tumorigenic cells within a tumor,
whilst the vast majority of cancer cells do not contribute
to tumor growth and would be unable to repopulate a
tumor after a given tumor cell ablative therapeutic inter-
vention [14]. Hypothetically, CSCs can self-renew indef-
initely, drive tumor growth and differentiate into
virtually all cell types found in a tumor [14], thereby
spawning heterogeneity. On the other hand, progenitors
and terminally differentiated cells are highly proliferative,
display lineage commitment, and have limited proliferative
potential (that is, finite number of cell divisions) and little
or no capacity to contribute to disease progression [14].
While the CSC model does not tackle the question regard-
ing the cell of origin, in particular whether cancers arise
from normal stem cells, it proposes that many cancers
may be hierarchically organized [19].
CSCs are described operationally, by challenging cancer
cells for their ability to form tumors in a relativelypermissive environment (that is, immunosuppressed mice)
[14]. The identification of the population able to form tu-
mors under these settings is often defined on the basis of
cell-surface markers, sometimes derived from the analysis
of normal stem cells in the tissue of origin. In the case of
breast cancer, the existence of stem-like cells was inferred
in a study demonstrating that as few as 100 CD44+CD24-/
low breast cancer cells could efficiently form tumors when
injected into mice [20], whereas the efficiency of cells of
other phenotypes was non-existent or significantly lower.
It was clear, however, that the CD44+CD24-/low surface
markers are enriched for tumorigenic cells in some, but
not all, breast cancers [20]. The validity of the combin-
ation of these markers as a definition of breast CSCs has
been called into question [21], and additional markers
have been reported (for example, ALDH1 [22]).
The tenets of the CSC hypothesis are being disputed,
given the evidence demonstrating the existence of a dy-
namic equilibrium between differentiated cells and CSCs
[23], whereby not only CSCs can differentiate into ter-
minally differentiated cells, but terminally differentiated
cells can also de-differentiate into a CSC state, and the
overlap between some phenotypic characteristics of
CSCs and the phenomenon of epithelial-to-mesenchymal
transition. Hence, in some contexts, the CSC phenotype
may represent a state that cancer cells within a tumor can
acquire rather than a discrete population of cancer cells
that constantly display those properties. Additionally, it is
clear that the definition of CSCs is assay-dependent and
may not accurately reflect the true physiology in humans
[24]. Xenotransplantation assays applied to breast cancer
may only identify cells capable of engraftment in particu-
larly permissive (micro)environments. In addition, there is
now direct evidence to demonstrate that at least in some
types of cancer (that is, acute lymphoblastic leukemia)
intra-tumor genetic heterogeneity is found not only in ter-
minally differentiated cells, but also in the CSC population
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review on the CSC hypothesis and its limitations, readers
are referred to Meacham and Morrison [14].
The CSC hypothesis and the extensive intra-tumor gen-
etic heterogeneity observed in some tumors (see below)
are not trivially reconciled. For instance, in tumors with
high degree of genetic heterogeneity, phenotypic and/or
functional differences between cells may reflect variations
at the genetic level rather than a CSC differentiation hier-
archy [14]. Therefore, integrating tumorigenic potential
and genetic heterogeneity studies is germane for a more
representative picture of the extent to which individual
tumorigenic cells contribute to genetic diversification.
The clonal evolution model
The clonal evolution model posits that although most
neoplasms arise from a single cell, cancer cells have
varying degrees of genetic instability and acquire add-
itional genetic aberrations during tumorigenesis and
tumor evolution. This process leads to the development
of a cancer cell population that, albeit clonal in origin, is
composed of multiple subpopulations that, in addition
to the founder genetic events, harbor private genetic
aberrations. In this model, the modal clone (that is, the
most frequent clone) in the tumor cell population is de-
fined by the tumor cell characteristics and the constella-
tion of selective pressures it is subjected to. A simplistic
model of clonal evolution is portrayed as a succession of
clonal expansions, where each round is driven by the ac-
quisition of additional random mutations [2,13] that can
be deleterious, neutral or confer a biological advantage
(that is, proliferation and survival). The latter may result in
clonal expansion [15]. It is important to note that not all
clonal expansions may be triggered by genetic events;
epigenetic mechanisms, such as DNA methylation, histone
modification, nucleosome positioning, and microRNA
expression affecting the regulation of gene expression or
creating permissive characteristics that would result in a
substantial increase in fitness of a given clone, may also
play a role.
This linear path of clonal expansions is arguably sim-
plistic and only conveys the key mutational events that
drive progression, namely 'driver' mutations. The acqui-
sition of such mutations, however, is often accompanied
by 'passenger' alterations (hitchhiker mutations equiva-
lent in evolution theory) that seem to confer no selective
advantage or have no phenotypic manifestation under a
given set of selective pressures [15]. Importantly, a given
mutation can change from a passenger to a driver aber-
ration should the selective pressures change. In addition,
epistatic interactions may result in phenotypes that differ
from those inferred by the sum of the phenotypes
caused by each of the mutations [26]. As tumors pro-
gress, the mutational rate may vary [27], leading togenetic diversification within the tumor as the clones
harboring new mutations that are neutral and some of
the less-fit clones may be produced more rapidly than
they are eliminated [15,27]. Tumors with higher genetic
complexity (that is, with a larger variety of clones harbor-
ing private mutations or more private mutations in each
clone) have a greater variety of genetic aberrations to be
subjected to selective pressures, and, consequently, the
probability of the existence of a clone that can be fit under
a new set of selective pressures is greater than in tumors
with low levels of intra-tumor genetic heterogeneity [2].
Intra-tumor genetic heterogeneity in breast
cancer
Darwinian evolutionary rules appear to govern the som-
atic changes that constantly occur within a tumor. With
the advent of MPS it has become possible to establish
the existence of intra-tumor genetic heterogeneity within
a primary tumor and between a primary tumor and its
metastasis. The seminal study by Gerlinger and col-
leagues [6] has elegantly demonstrated both phenomena
in kidney cancers. In breast cancer, evidence of intra-
tumor genetic heterogeneity has been documented by
cytogenetic analysis, chromosomal and microarray-based
comparative genomic hybridization (CGH) and, more
recently, MPS analysis [5,7,9-11,17,28-32]. Importantly, a
recent study by Shah and colleagues [11] has demon-
strated that the intra-tumor genetic heterogeneity found
in breast cancers may affect even known driver genetic
aberrations, such as TP53 and PIK3CA somatic mutations.
Furthermore, there is also evidence to demonstrate that,
in individual breast cancers, subclonal populations of can-
cer cells may exist across different geographical regions of
a tumor (spatial heterogeneity) or evolve over time
between the primary tumor and a subsequent local or
distant recurrence (temporal heterogeneity) [7,9,12,31].
Causes of intra-tumor genetic heterogeneity
Evolutionary trajectories of tumors are determined by
population size, mutation rate and selective pressures
[17]. Elevated mutation rate (that is, genomic instability)
is a common feature in cancers [27]. This instability can
be caused by inherited or somatic aberrations in genes
that maintain genome instability, or can be caused by
extrinsic mutagens such as cigarette smoke, ultraviolet
light and chemotherapy [15]. The aberration spectra of
cancer cells often reflect the signatures of the mechan-
ism of genomic instability [15]. Genome-wide profiling
of somatic mutations in breast cancers revealed substan-
tial variations in the total number of mutations and the
type of mutations [32,33], suggesting that the mutational
processes that generate these genomic landscapes vary.
It was hypothesized that some of these mutational pat-
terns may be associated with homologous recombination
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Moreover, regional hypermutation of C > T at TpCpX
trinucleotides, known as kataegis, has been documented
in breast cancers [32]. Hence, cancer initiation and pro-
gression are dependent on mutations and chromosomal
rearrangements that can accumulate either gradually
over time (gradualism) or in a single catastrophic event,
such as chromothripsis (punctuated equilibrium) [34].
The interaction of genomic instability and selective
pressure results in intra-tumor heterogeneity; selective
pressures, however, are not constant, and may vary
spatially due to differences in the (micro)environment,
changes in endocrine stimuli, and exogenous parameters
(for example, therapeutic intervention) [1]. Thus, al-
though most cells within a tumor are thought to have a
clonal origin, genomic instability and the dynamic nature
of selective pressure can lead to multiple routes of gen-
etic diversification within the adaptive landscapes of tis-
sue ecosystems [15], and can ultimately result in a
genetically, epigenetically and phenotypically diversified
tumor.
Spatial heterogeneity
Spatial heterogeneity refers to the genetic variation
across different regions within a single tumor. Histo-
logical heterogeneity within a tumor is a frequent
phenomenon in breast cancers, and one of the defining
characteristics of metaplastic breast cancers (Figure 1).
In a proof-of-principle study, our group utilized
microarray-based CGH, TP53 sequencing and fluores-
cence in situ hybridization (FISH) to determine the ex-
tent of genetic heterogeneity between morphologically
distinct areas of individual metaplastic breast cancers
[31]. In all but one case, the histologically distinct com-
ponents of the tumors were shown to be clonal based on
the presence of identical TP53 somatic mutations and
similar copy number aberrations. In two cases, however,
the morphologically distinct components, albeit clonal,
displayed distinct repertoires of gene copy numberFigure 1 Spatial and temporal heterogeneity. Heterogeneity may be pr
tumor harbor different repertoires of genetic aberrations (spatial heterogen
(temporal heterogeneity).aberrations, including high-level focal amplifications
[31]. These observations are consistent with the notion
that morphologically distinct areas of a cancer are at
least coincidental with, if not underpinned by, different
repertoires of genetic aberrations. Similar observations
were made in a case of a triple-negative breast cancer
with focal apocrine differentiation [35].
Spatial intra-tumor genetic heterogeneity has also been
documented irrespective of differences in the histological
features of the areas analyzed. CGH analysis of geo-
graphically separate sectors of primary breast cancers, ir-
respective of the local histological characteristics, has
revealed varying levels of genetic heterogeneity within
cancers; monogenomic tumors are characterized by the
presence of a single major clonal subpopulation with a
stable genome, whereas polygenomic cancers harbor
multiple genetically distinct subpopulations, which may
occupy the same or separate anatomic locations [7].
Similar observations were made by means of single cell
sequencing analysis [9]. Interestingly, in two polyge-
nomic breast cancers, subpopulations with increasing
genomic complexity followed a linear pattern geograph-
ically in the tumor [7] and in one of the two tumors, a
subclonal KRAS amplification was identified. The tumor
cells that harbored the KRAS amplification intermixed
with those that did not, suggesting that genetically dis-
tinct tumor populations do not necessarily segregate
spatially [7,9].
Temporal heterogeneity
There is evidence to demonstrate that tumors evolve
over the course of the disease between the primary
tumor and local or distant recurrences (Figure 1). Even
though genomic analysis of primary breast tumors and
their metastases demonstrated their clonal relatedness
and revealed similarities in their repertoire of somatic
genetic aberrations, differences in their genomes have
been systematically documented [28,30,36,37]. While
synchronous metastases tend to be largely similar toesent within a given tumor, such that the different regions of the
eity), or during the course of disease progression
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toire of genetic alterations [30,37], 31% of cases of pri-
mary breast cancers and their metachronous metastases
revealed significant differences in gene copy number by
CGH and FISH [36]. In a more recent study, whole-
genome sequencing of the relapse of a lobular breast
cancer 9 years after diagnosis revealed that some of the
mutations present in 1 to 13% of the cells in the original
tumor were enriched in the relapse tumor [10]. In a dif-
ferent report, the primary tumor appeared to have more
clonal diversity than the metachronous brain metastasis
based on the frequencies of mutations and structural
variants, suggesting chemotherapy and/or the micro-
environment contributed to the temporal heterogeneity
in this case [8]. These observations illustrated that the
metastatic lesions share somatic genetic aberrations with
their primary tumor, but that their modal populations
differ, suggesting that metastases may stem from a single
or a limited number of clones from the primary tumor
or even from clones present in other metastases rather
than from the clones present in the primary tumor [6].
Based on these observations, it is also plausible that the
neoplastic populations of primary tumors and their me-
tastases may undergo parallel and independent evolu-
tionary routes.
Another potential temporal evolutionary bottleneck is
the progression from in situ to invasive disease [17],
given that, chronologically, the latter follows the former,
in cases where a given in situ lesion is the actual precur-
sor of the invasive cancer. Although ductal carcinoma in
situ (DCIS), a non-obligate precursor of invasive breast
cancer, and the infiltrating counterparts appear genetically
similar, they occasionally present qualitative differences in
phenotypes and genotypes [38,39]. This observation indi-
cates that, despite their clonal relatedness, some invasive
tumors may derive from non-modal populations of neo-
plastic cells within the adjacent DCIS [38]. Moreover, al-
though the modal populations of synchronously diagnosed
ipsilateral DCIS and invasive carcinomas are genetically
similar, intra-tumor genetic heterogeneity seems to occur
early in breast cancer development [38,39], and clonal se-
lection appears to take place during the progression from
in situ to invasive disease [38,39].
Many therapeutic failures can be attributed to the out-
growth of clones that harbor specific resistance mecha-
nisms and were present before the onset of therapy due
to intra-tumor genetic heterogeneity [2,17,26]. For ex-
ample, gefitinib resistance in patients with EGFR mutant
non-small cell lung cancers has been shown to be medi-
ated in some cases by the selection of cancer cells har-
boring the EGFR(T790M) gatekeeper mutation and/or
MET gene amplification [40]. Furthermore, resistance to
poly(ADP) ribose polymerase inhibitors and platinum-
based chemotherapy in cancer patients harboring aBRCA1 or BRCA2 germline mutation is mediated in a
proportion of cases by the acquisition of revertant muta-
tions or intra-genic deletions that restore the open reading
frame of BRCA1 or BRCA2 [41,42]. It is possible, on the
basis of the data currently available, that these secondary
somatic genetic events affecting BRCA1 or BRCA2 may
precede the therapeutic intervention [26,42].
Approaches to characterize intra-tumor genetic
heterogeneity
Given the clinical implications of intra-tumor heterogen-
eity, a remaining question is to identify the optimal
means to assess this phenomenon, and to monitor
spatial and temporal heterogeneity (Figure 2).
Tumor bulk sequencing
Most cancer genomics studies currently involve the
sequencing of DNA extracted from millions of cells of the
tumor bulk [6,11,33], which gives the average mutant
allele fraction and average allelic copy number. This
approach, however, only provides a compound measure of
the underlying clonal complexity and the clonal frequen-
cies of mutations and copy number alterations have to be
inferred statistically using algorithms such as ABSOLUTE
[43] or PyClone [11]. ABSOLUTE jointly estimates tumor
purity and ploidy from the observed copy number profiles
(and mutational repertoire, if available) accounting for
subclonal aberrations [43]. The clonal frequency of a given
aberration is then inferred from the estimated tumor
purity, ploidy, and local copy number alterations and is
classed as clonal or subclonal. PyClone uses a hierarch-
ical Bayesian model to estimate the clonal frequencies
of mutations, also accounting for sequencing errors
[11]. A Dirichlet process is used to estimate the clonal
frequencies, and mutations with similar clonal frequen-
cies are clustered. Although not a definite proof, cluster-
ing provides clues to which genetic aberrations may
occur together in the same cells [11,44]. These methods
are highly sensitive to the accurate estimation of local
copy number variation, which is not trivially obtained,
as cells within a given tumor do not always have the
same copy number alterations, as illustrated by single
cell sequencing studies [9]. For both ABSOLUTE and
PyClone, however, prior knowledge of the tumors is re-
quired to obtain optimal results. For instance, even
though ABSOLUTE integrates recurrent cancer karyo-
type models to identify the most common karyotype
that would explain the data, more appropriate results
may be obtained by overriding default estimates with
prior knowledge on either tumor purity or ploidy. Fur-
thermore, detection of subclonal populations is limited
by the error rate of the sequencing platform and aberra-
tions in rare cells may escape detection using standard
sequencing depths (100x to 250x coverage). Finally, to
Figure 2 Approaches to characterize heterogeneity. Tumor bulk sequencing: massively parallel sequencing of millions of tumor cells can be
employed to assess the allele frequencies of mutations. Using statistical methods, the clonal frequencies of these mutations can be inferred.
Detection of ultra-rare mutations: mutations that are present in rare populations of cancer cells (that is, comprise <1% of the tumor cell
population) can be identified using high-fidelity sequencing, such as allele-specific tagging of DNA molecules, such that only alterations found on
both strands are defined as mutations. Single-molecule sequencing: DNA is extracted from tumor cells and sequenced on a single-molecule
sequencing platform (for instance, the Pacific Bioscience RS system). Single-cell sequencing: tumors are dissociated into single cells. DNA from
single cells is amplified and sequenced using massively parallel sequencing to genotype individual cells. In situ topological genotyping: DNA or
mRNA is amplified in situ on histological sections of the tumor, allowing for the genotyping of the cancer cells within the tumor without losing
anatomical and histological information.
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based on bulk sequencing, comprehensive sequencing
of the tumor genome is required (that is, currently, at
least whole exome sequencing). Despite all these chal-
lenges, bulk sequencing remains a popular choice given
its cost-effectiveness.
Detection of ultra-rare mutations
Although standard next-generation sequencing tech-
nologies have the capacity to generate hundreds of bil-
lions of nucleotides of DNA sequence in a single
experiment, the practical limit of detection is imposed
by errors introduced during sample preparation and
sequencing. For the mainstream MPS platforms such as
Ion Torrent and Illumina platforms, the sequencing
error rate is reported to range from 0.26% to 1.71% [45].
These scattered sequencing mistakes become very prob-
lematic when studying mutations present in <1% of cells[46]. A variety of improvements in biochemistry, sample
preparation and data processing have been developed to
enhance sequencing accuracy. For example, a tagging
method (SafeSeqS) based on labeling single-stranded
DNA fragments has been developed and allows for an
observed mutation frequency of <0.001% mutations/base
pair [47]. More recently, Schmitt and colleagues [46] de-
veloped an approach for tag-based error correction
called Duplex Sequencing that greatly reduces errors by
independently tagging and sequencing the two strands
of a DNA duplex. This method has a theoretical back-
ground error rate of less than one error per 109 nucleo-
tides sequenced, allowing the detection of ultra-rare
variants in heterogeneous populations. However, nucleo-
tides artifactually introduced during the initial round of
PCR amplification cannot be accurately detected as er-
rors, even with a tagging technique, if the artifactual mu-
tation is propagated to all subsequent PCR duplicates
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of mutations present in <1% of cancer cells are eagerly
awaited.
Single-molecule sequencing
Bulk tumor sequencing may also be performed using
single-molecule sequencing technologies. Compared to
MPS, single-molecule sequencing eliminates the need
for PCR amplification, and thus the biases introduced by
PCR amplification. This approach requires less starting
material, has faster turnaround time, and produces lon-
ger reads (3 kb) [48] that are advantageous for identifica-
tion of genomic rearrangements. Profiling intra-tumor
heterogeneity by single-molecule sequencing, however,
shares the same challenges as bulk sequencing by con-
ventional MPS, in that it is not a direct measure of het-
erogeneity and the subclonal architecture can only be
inferred. Furthermore, increased read length does not
benefit calling subclonal point mutations and is likely
only useful in samples with optimal DNA quality. The
high sequencing error rate at 13%, compared to 0.26% to
1.71% for the most frequently employed MPS platforms
[45,48], is particularly detrimental in the context of het-
erogeneity, as sequencing error may be mistaken for
genuine subclonal mutations. Finally, the throughput of
single-molecule sequencing is too low for heterogeneity
studies. Further technological developments are required
for the successful use of single-molecule sequencing in
the characterization of intra-tumor genetic heterogeneity
in cancers.
Single-cell sequencing
Currently, the most objective way to assess heterogeneity
is single-cell sequencing. In contrast to bulk sequencing
either by MPS or single-molecule sequencing, single-cell
sequencing allows for the direct inference of clonal ge-
notypes (that is, identification of the repertoire of gen-
etic alterations in each tumor cell that composes a
tumor [44]). In this effort, Navin and colleagues [9] have
successfully developed and applied MPS to single cells
(that is, single nucleus sequencing), and conclusively
demonstrated that many breast cancers are composed of
multiple genetically distinct subclones. Currently, the
costs and time required for whole exome or whole gen-
ome single cell sequencing of tumors are prohibitive for
clinical use. Furthermore, the relevance of single cell se-
quencing methods in the diagnostic arena is still unclear
since sequencing data derived from single cells do not
provide any direct information on the remaining tumor
cell population. In addition, whilst structural variations
can be reliably identified using single-cell sequencing,
the genome-wide assessment of mutations in single cells
is still challenging due to artifacts introduced by whole
genome amplification [49]. One potential use of single-cell sequencing may lie in the characterization of CTCs
(see below); it remains to be determined, however,
whether CTCs are representative of the whole tumor
and if those cells are likely to constitute the ones that
mediate the metastatic progression of cancers [50].
In situ topological genotyping
Given the spatial heterogeneity in tumors, methodologies
that allow for in situ topological genotyping, assessment
of gene copy number aberrations, and expression and/or
activation of the protein products of genes targeted by
genetic hits provide detailed geographical information for
the inference of clonal structure and tumor topology that
is complementary to that provided by bulk and single-cell
sequencing. Techniques routinely employed in pathology
laboratories, including in situ hybridization and immuno-
histochemistry, using robust methods and validated anti-
bodies, have been successfully employed not only to
unravel intra-tumor genetic heterogeneity in cancers
[38,39] but also to provide important information on the
expression and activation of genes targeted by gene copy
number aberrations (for example, gene amplification) and
mutations or their downstream targets. Furthermore, a
combination of FISH and immunohistochemistry has
proven useful in the development of computational
models to infer tumor growth patterns and evolutionary
dynamics, and also in the characterization of the interac-
tions between intra-tumor heterogeneity and pathological
complete response in breast cancers [51]. Novel tech-
niques, including the synchronous in situ detection of
multiple expressed mutations, based on padlock probes
and in situ target-primed rolling-circle amplification [52],
have also been successfully applied to the detection of
somatic point mutations, the discrimination between
members of a gene family and for multiplex detection of
transcripts in human and mouse cells and tissue. In
addition to multiplex geographical genotyping of tumors,
in situ analysis of mRNA has a detection resolution that
may allow for the study of allele-specific expression dir-
ectly on tissue samples. These features render the ap-
proaches described above an exciting complement to both
bulk and single-cell sequencing genomics, where genetic
aberrations found in bulk or single cells can be traced
back to the tumor topology. This integrative approach
would not only define regions of dominance of specific
driver genetic events, but also provide an integrated view
of the potential functional consequences of these genetic
aberrations on gene and protein expression, and pathway
activation.
Assessing intra-tumor heterogeneity: clinical
applications
It is undeniable that a high degree of phenotypic and
genetic intra-tumor heterogeneity exists in breast tumors,
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both diagnosis and disease management. Given the dis-
cordance in the mutational repertoire between primary
tumor and metastatic lesions within the same patient
[6,8], a single biopsy is unlikely to represent accurately the
genomic landscape of a patient’s cancer. On the other
hand, serial tumor sampling at crucial time points (for
example, development of metastatic disease or progres-
sion after initial response to systemic therapy) may help
monitor the temporal heterogeneity [12]. In many cases,
however, multiple sampling is not clinically feasible.
Tumor specimens are routinely formalin-fixed paraffin-
embedded (FFPE) to preserve their histology, and these
currently represent the largest source of clinical material
but are underused in large scale whole exome or whole
genome studies due to technological challenges. The abil-
ity to perform MPS on DNA and RNA material extracted
from FFPE tissues will greatly increase the availability of
material amenable to the characterization of intra-tumor
heterogeneity. Currently, targeted sequencing using cap-
ture panels for DNA derived from FFPE samples allows
the detection of clonal and subclonal mutations [53].
While the technology is improving such that routine
whole-exome sequencing will soon be possible, translating
single-cell methods into the clinic using FFPE material
presents a bigger challenge.Figure 3 Circulating tumor cells and circulating cell free DNA. Circulat
from tumor cells, are obtained through serial collection of blood samples. G
genetic heterogeneity of a cancer, and enable monitoring of its response t
emergence of resistant clones.As CTCs and circulating cell-free plasma DNA (cfDNA)
are likely to originate from tumor cells and thus correlate
with disease burden and may overcome sampling bias,
blood biomarkers may serve as a surrogate for spatial het-
erogeneity and as a marker for temporal heterogeneity
(Figure 3). The accurate detection and molecular profiling
of CTCs remain obstacles to using CTCs as a surrogate
for heterogeneity. In particular, the most popular CTC
capture method, CellSearch, relies on the detection of the
surface epithelial marker EpCam; it is unclear, however,
whether all CTCs from epithelial tumors express EpCam
and are detected by this methodology [54]. Furthermore,
even in metastatic breast cancer patients, a median of only
five CTCs are detected per 7.5 ml blood [50]. Given the
rarity of CTCs and the high possibility of contamination
with non-tumor cells, the molecular profiling technique
used for their analysis needs to be remarkably sensitive to
be able to detect the tumor-specific aberrations. As a
surrogate for heterogeneity, whether CTCs are truly
representative of the entire tumor or of more genetically
advanced clones remains to be seen.
In contrast to the challenges faced in the molecular
profiling of CTCs, the profiling of cfDNA requires se-
quencing and bioinformatic methods that are capable of
detecting ultra-rare aberrations in fragmented DNA.
The recent proof-of-principle study in which temporaling tumor cells and cell free DNA, which is at least in part derived
enetic analysis of these samples may provide information about the
o therapeutic interventions, the progression of the disease, and the
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PIK3CA and TP53 in cfDNA from breast cancer patients
suggests that it is a viable, sensitive and real-time surro-
gate for tumor burden [55]. That study, however, was
limited to metastatic cancers and whether cfDNA would
constitute an optimal marker for patients with early-
stage breast cancer is currently unknown. Furthermore,
the specific mutations were detected in only 30 of 52 pa-
tients, suggesting that, in its current form, its clinical
utility is uncertain. It is plausible that in the remaining
patients the proportion of cfDNA is below the detection
of conventional MPS methods, arguing for more sensi-
tive technologies.
In addition to monitoring progression using specific
mutations, de novo identification of aberrations in
cfDNA may help in assessing the overall heterogeneity
and identifying genetic aberrations responsible for drug
resistance. Although it has recently been reported that
exome sequencing of plasma DNA is possible and that
many of the mutations identified are concordant be-
tween plasma and synchronous metastasis biopsies, in
two of the cases studied, 38.4% and 80.7% of the muta-
tions were found in either only the plasma or the metas-
tasis [56]. In particular, in one case, 76.6% of the
mutations were found only in the metastasis with allele
frequencies of <20% [56], suggesting that at the sequen-
cing depth employed using the standard sequencing
methods, plasma DNA was not a comprehensive repre-
sentation of the overall intra-tumor heterogeneity. The
use of high-fidelity high-depth sequencing methods may
increase the sensitivity for the detection of subclonal
mutations present in tissues and plasma.
Conclusion
The realization that tumors are composed of several
subclones of tumor cells that, in addition to the founder
genetic events, harbor private mutations, some of which
constitute bona fide driver genetic aberrations, has re-
sulted in a paradigm shift in regards to our understand-
ing of cancers. Understanding the concept of intra-
tumor genetic heterogeneity is providing answers to
clinical questions that had historically baffled oncolo-
gists, pathologists and scientists. By the same token, the
degree of genetic heterogeneity observed within cancers
is undoubtedly a daunting observation from the preci-
sion medicine standpoint. We would argue, however,
that by comprehensively cataloguing this phenomenon
and identifying the mechanisms that result in its emer-
gence, novel approaches to targeting cancers may
emerge. In fact, recent advances in next generation se-
quencing analysis have opened up new possibilities for
the way we approach the problem; despite the current
statistical and technological challenges that have yet to
be resolved, the opportunities are enormous.Abbreviations
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